Clinical Trials Browser

Phase 2 × Recruiting × Has announcements × Clear all

NCT04634552 2026-03-17

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 2 FDA

Neuroblastoma

NCT04482309 2026-01-21

DPT02

Phase 2 Recruiting

468 enrolled 1 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT02227251 2025-10-01

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Recruiting

244 enrolled 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04775485 2025-04-10

FIREFLY-1

Phase 2 Recruiting

141 enrolled 1 FDA

CNSOther solid neoplasm

Low-grade Glioma